Repligen to Report First Quarter 2021 Financial Results
April 20 2021 - 7:30AM
Repligen Corporation (NASDAQ:RGEN) today announced that the Company
will report its first quarter 2021 financial results on Tuesday,
May 4, 2021. The Company will issue a press release before the
market opens and will host a conference call at 8:30 a.m. EDT to
discuss business updates and financial results for the three-month
reporting period ended March 31, 2021.The conference call will be
accessible by dialing toll-free (844) 274-3999 for domestic callers
and (412) 317-5607 for international callers. No passcode is
required for the live call. In addition, a webcast will be
accessible via the Investor Relations section of the Company’s
website. Both the conference call and webcast will be archived for
a period of time following the live event. The replay dial-in
numbers are (877) 344-7529 for callers in the U.S., (855) 669-9658
for callers in Canada and (412) 317-0088 for international callers.
Replay listeners must provide the passcode 10155233.
About
Repligen CorporationRepligen Corporation is a global life
sciences company that develops and commercializes highly innovative
bioprocessing technologies and systems that increase efficiencies
in the process of manufacturing biological drugs. Our primary
customers are biopharmaceutical drug developers and contract
development and manufacturing organizations (CDMOs) worldwide. Our
corporate headquarters are located in Waltham, Massachusetts, with
additional administrative and manufacturing operations worldwide.
The majority of our manufacturing sites are located in the U.S.
(California, Massachusetts, New Jersey and New York), and outside
of the U.S. we have sites in Estonia, Germany, Ireland, the
Netherlands and Sweden.This press release may contain
forward-looking statements within the meaning of the federal
securities laws. Investors are cautioned that statements in this
press release which are not strictly historical statements
including, without limitation, statements identified by words like
“believe,” “expect,” “may,” “will,” “should,” “seek,” or “could”
and similar expressions, constitute forward-looking statements.
Such forward-looking statements are subject to a number of risks
and uncertainties that could cause actual results to differ
materially from those anticipated, including risks discussed from
time to time in our filings with the Securities and Exchange
Commission. We expressly disclaim any responsibility to update any
forward-looking statements, except as required by law.
Repligen Contact: Sondra S. NewmanGlobal Head of
Investor Relations(781) 419-1881investors@repligen.com
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024